Objective: To study the efficacy of Cinobufagin capsule combined with hydroxycamptothecin in the treatment of patients with advanced esophageal cancer. Methods: 120 patients with esophageal cancer in our hospital from January 2015 to May 2017 were selected as the study subjects. All patients were divided into control group and treatment group according to the treatment plan, 60 cases in each. The patients in the control group were given hydroxycamptothecin, on top of which, the treatment group was given Cinobufagin capsule daily. The objective remission rate, clinical benefit rate, pain degree, quality of life and side effects were compared between the two groups. The level of tumor markers and 1-year survival rate of the two groups were compared before and after treatment. Results: After treatment, the clinical benefit rate, objective remission rate and quality of life of the treatment group were significantly higher than those of the control group. The pain degree of the treatment group was significantly lighter than that of the control group, and the difference was statistically significant (P<0.05); after treatment, the two groups of patients with CEA, CA19-9 and CA72-4 were significantly better than those before the treatment. The level of tumor markers in the treatment group was significantly better than that in the control group (P<0.05), and there was no significant difference in the 1 year survival rate and the side effects in the two groups (P>0.05). Conclusion: Cinobufagin capsule combined with hydroxycamptothecin has good clinical efficacy in the treatment of patients with advanced esophageal cancer. It can effectively improve the quality of life and the rate of clinical benefit, improve the level of tumor markers, reduce the degree of cancer pain and have high safety, which is worthy of clinical promotion. |
[1] 中华人民共和国.中国统计年鉴2015[M].北京:中国统计出版社,2015.
[2] XIA J,INAGAKI Y,GAO J,et al.Combination of cinobufacini and doxorubicin increases apoptosis of hepatocellular carcinoma cells through the Fas- and mitochondria-mediated pathways[J].Am J Chin Med,2017,45(7):1537-1556.
[3] 肖晓光,梅齐,李扬,等.华蟾素胶囊联合化疗治疗晚期肺癌的临床研究[J].实用肿瘤杂志,2015,30(5):469-473.
[4] 柯红,崔洁,金锦莲,等.华蟾素胶囊联合CAF方案治疗中晚期乳腺癌的临床效果分析[J].世界中医药,2017,12(10):2358-2361.
[5] 李方,李楠.华蟾素胶囊联合奥沙利铂、替吉奥方案治疗中晚期结直肠癌临床疗效[J].临床军医杂志,2016,44(10):1033-1036.
[6] EDGE S B,COMPTON C C.The American Joint Committee on Cancer:the 7th edition of the AJCC cancer staging manual and the future of TNM[J].Ann Surg Oncol,2010,17(6):1471-1474.
[7] FRIENDLER A H,ETTINGER R L.Karnofsky performance status scale[J].Spec Care Dentist,2010,29(4):147-148.
[8] 严广斌.视觉模拟评分法[J/OL].中华关节外科杂志(电子版),2014,8(2):34.
[9] 美国东部肿瘤协作组.抗癌药急性及亚急性毒性反应分度标准(WHO标准)[J].癌症,1992,7(3):254-280.
[10] WATANABE H,OKADA M,KAJI Y,et al.New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)[J].Gan To Kagaku Ryoho,2009,36(13):2495-2501.
[11] 袁梅美,惠起源.华蟾素抗恶性肿瘤的研究进展[J].中国医药导报,2014,11(2):44-46.
[12] 戚诚,赵晓东,刘博,等.华蟾素胶囊联合同步放化疗治疗局部晚期食管癌的疗效分析[J].中国肿瘤临床与康复,2017,24(5):525-528.
[13] 张霞,陈迎平,祁峰.华蟾素注射液对人肝癌肿瘤细胞HepG_2增殖抑制作用观察及其作用机制研究[J].湖北中医药大学学报,2016,18(6):25-28.
[14] 薛瑞,张青松,张玉洁,等.华蟾素对乳腺癌MCF-7移植瘤裸鼠的抗肿瘤作用及机制研究[J].实用药物与临床,2014,17(7):815-817.
[15] 王宁军,芦殿荣,杨柳,等.华蟾素缓解癌性疼痛作用机制的研究进展[J].世界中西医结合杂志,2016,11(4):590-592.
[16] 贾小晴,孙萍.华蟾素抗肿瘤成分及作用机制研究进展[J].辽宁中医药大学学报,2017,19(3):215-217. |